6330534C20Rik Inhibitors

Chemicals classified as CCDC160 Inhibitors are not directly targeting the CCDC160 protein but are involved in modulating broader cellular processes that can indirectly influence the stability, expression, or function of CCDC160. These compounds can have a wide range of effects on protein homeostasis, including protein folding, biosynthesis, trafficking, and degradation. Compounds such as Geldanamycin and 17-AAG target the Hsp90 chaperone, which assists in the correct folding of many proteins. Disruption of Hsp90 function by these inhibitors can lead to a destabilization of its client proteins. If CCDC160 relies on Hsp90 for its folding or stability, these inhibitors can indirectly affect its function. Cycloheximide and Puromycin are protein synthesis inhibitors that halt the translation of mRNA into proteins, thereby reducing the overall levels of proteins like CCDC160. MG-132 and Chloroquine disrupt protein degradation pathways, the former by inhibiting the proteasome and the latter by affecting lysosomal function, which can lead to altered levels of proteins, including potentially CCDC160.

Brefeldin A and Monensin interfere with protein trafficking, the former by inhibiting the function of the Golgi apparatus and the latter by disrupting ion gradients, which are crucial for the trafficking of proteins. Tunicamycin's inhibition of N-linked glycosylation can impact proteins that require this modification for their function. Rapamycin inhibits the mTOR pathway, which is a central regulator of cell growth and protein synthesis, potentially affecting the synthesis and function of CCDC160. Lithium Chloride's impact on GSK-3 activity and Wnt signaling can modulate protein stability and expression. Lastly, Withaferin A is known to inhibit protein aggregation and can influence the proteostasis network within which CCDC160 may function.